慢性阻塞性肺病 (COPD):KOL Insight

本報告提供慢性阻塞性肺病 (COPD) 治療藥調查，關於已上市藥及開發平台藥物的未來性由KOL考察的彙整資料。

本報告，授權用戶可從附加文件存取Report Highlights幻燈片和KOL Bulletins。

目錄

摘要整理

治療流程

調查目的

ICS/LABA/LAMA三倍聯合治療

• 已上市藥
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK)
  • Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi)
  • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate; AstraZeneca)

生物學的治療藥

• 抗IL5開發平台療法
  • Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca)
• 抗IL4/IL13開發平台療法
  • Dupixent (dupilumab; Regeneron/Sanofi)
• 抗TSLP開發平台療法
  • Tezspire (tezepelumab; Amgen/AstraZeneca)
• 抗IL33開發平台療法
  • Itepekimab (REGN3500/SAR440340; Regeneron/Sanofi)
  • Astegolimab (RG6149; Roche)
  • Tozorakimab (MEDI3506; AstraZeneca)

磷酸二酯酶抑制劑

• 開發平台療法
  • Ensifentrine (RPL554; Verona)
  • Tanimilast (CHF 6001; Chiesi)

今後的治療範例

• 重要洞察的摘要

附錄

• KOL詳細內容

Verona's inhaled dual-action PDE inhibitor ensifentrine has the potential to be paradigm changing, but what barriers do KOLs identify that could hinder its uptake? Where do experts see Sanofi/Regeneron's anti-IL4/IL13 mAb Dupixent delivering value? Why, despite failure of prior Phase III studies, are KOLs are optimistic about anti-IL5 mAbs - GSK's Nucala and AstraZeneca's Fasenra? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (9)

ICS/LABA/LAMA triple combination therapies (21)

• Marketed therapies (21)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK) (5)
  • Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi) (11)
  • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate; AstraZeneca) (5)

Biological therapies (62)

• Anti-IL5 pipeline therapies (15)
  • Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (15)

• Anti-IL4/IL13 pipeline therapies (11)
  • Dupixent (dupilumab; Regeneron/Sanofi) (11)

• Anti-TSLP pipeline therapies (8)
  • Tezspire (tezepelumab; Amgen/AstraZeneca) (8)

• Anti-IL33 pipeline therapies (28)
  • Itepekimab (REGN3500/SAR440340; Regeneron/Sanofi) (10)
  • Astegolimab (RG6149; Roche) (10)
  • Tozorakimab (MEDI3506; AstraZeneca) (8)

Phosphodiesterase inhibitors (27)

• Pipeline therapies (27)
  • Ensifentrine (RPL554; Verona) (16)
  • Tanimilast (CHF 6001; Chiesi) (11)

Future treatment paradigm (15)

• Key insights summary (15)

Appendix (5)

• KOL details (5)
  • KOLs from the USA (1)
  • KOLs from Europe (3)